Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Next Previous
Trial Profile

A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapacitabine (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SEAMLESS
  • Sponsors Cyclacel Pharmaceuticals

Most Recent Events

  • 23 Aug 2021 Results assessing the survival benefit and safety of decitabine administered in alternating cycles with sapacitabine versus decitabine monotherapy in elderly patients with newly diagnosed acute myeloid leukemia, published in the Cancer.
  • 27 Mar 2019 According to a Cyclacel Pharmaceuticals media release, based on stratified and exploratory subgroup analyses and following consultation with three European regulatory authorities regarding a potential approval pathway for sapacitabine the Company intends to submit a request for scientific advice to the Scientific Advice Working Party (SAWP) of the European Medicines Agency.
  • 14 May 2018 According to a Cyclacel Pharmaceuticals media release, the company is planning to conduct regulatory authority meetings in 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top